Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Shares of biopharma company Viking Therapeutics ($VKTX) rose as high as 5% during the first hour of trading on Monday. The ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s ...

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.60, representing a 15.98% upside. In a report released today, J.P. Morgan also maintained a Hold rating on the ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. The company’s shares closed yesterday at $24.66. Take advantage of TipRanks Premium at 50% ...

On October 27, Nicolas Janvier, Head of North America Equities at Columbia Threadneedle Investments, joined CNBC television ...